Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death
NCT ID: NCT05446779
Last Updated: 2024-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
400 participants
OBSERVATIONAL
2022-02-03
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
China National Study of Adrenal Venous Sampling
NCT06192238
Evaluation of Patients After Cardiac Surgery: Novel Ultrasound Parameters for Quantification of Renal Perfusion & Analysis of Phenylephrines' Effect on Invasive Haemodynamics and Echocardiographic Measures
NCT04419662
Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome
NCT00586183
Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS)
NCT00773058
Management of Adrenal Emergency in Germany
NCT03426332
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sudden death
Unexpected witnessed death occurring within an hour of the onset of symptoms in a person with or without previously known cardiac disease without an extra-cardiac cause, or unexpected unwitnessed death without extra-cardiac cause occurring in the previous 24 hours
Adrenal aldosterone synthase (CYP11B2) staining
Immunoshistochemical diagnosis of primary aldosteronism
Adrenal cortisol synthase (CYP11B1) staining
Immunoshistochemical diagnosis of adrenal hypercortisolism
Histopathological analysis
Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
Control
Death because of an exogenic reason for sudden death such as trauma or suicide as a control group i.e. non-disease-induced sudden death
Adrenal aldosterone synthase (CYP11B2) staining
Immunoshistochemical diagnosis of primary aldosteronism
Adrenal cortisol synthase (CYP11B1) staining
Immunoshistochemical diagnosis of adrenal hypercortisolism
Histopathological analysis
Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adrenal aldosterone synthase (CYP11B2) staining
Immunoshistochemical diagnosis of primary aldosteronism
Adrenal cortisol synthase (CYP11B1) staining
Immunoshistochemical diagnosis of adrenal hypercortisolism
Histopathological analysis
Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Terminal disease
3. Institutionalized patients
35 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Finnish Institute for Health and Welfare
OTHER_GOV
University of Helsinki
OTHER
Tampere University Hospital
OTHER
Tampere University
OTHER
Helsinki University Central Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Niina Matikainen
M.D., Ph.D, , Assoc. Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Niina Matikainen, MD, PhD, Assoc Prof
Role: PRINCIPAL_INVESTIGATOR
Helsinki University Central Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Endocrinology, Helsinki University Hospital and University of Helsinki
Helsinki, , Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ylanen A, Isojarvi J, Virtanen A, Leijon H, Vesterinen T, Aro AL, Huhtala H, Kokko E, Porsti I, Viukari M, Nevalainen PI, Matikainen N. Adrenal aldosterone synthase (CYP11B2) histopathology and its association with disease-induced sudden death: a cross-sectional study. Lancet Reg Health Eur. 2025 Feb 6;51:101226. doi: 10.1016/j.lanepe.2025.101226. eCollection 2025 Apr.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
THL/5008/5.05.00/2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.